Larimar Therapeutics (NASDAQ:LRMR – Free Report) had its price target reduced by Robert W. Baird from $13.00 to $10.00 in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback